Release Date: 23/12/10 17:45 Summary: Challenger Group Securities Dealing Policy Price Sensitive: No Download Document 299.45KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%